medwireNews: The EMA’s Committee for Medicinal Products for Human Use has recommended the approval of semaglutide 2.4 mg/day for the management of obesity.
Semaglutide will be available in concentrations of 0.25, 0.5, 1.0, 1.7, and 2.4 mg. As stated in the positive opinion, the medication is intended to be “an adjunct to a reduced-calorie diet and increased physical activity” to assist weight loss or weight maintenance in people who have obesity or are overweight and have a weight-related comorbidity.
The medication was tested in this indication in the STEP trial series. Results of those so far published include an average 14.9% reduction in bodyweight during 68 weeks of semaglutide 2.4 mg treatment in people with obesity in STEP 1, and a significantly greater bodyweight reduction with semaglutide 2.4 mg versus 1.0 mg in people with obesity and type 2 diabetes in STEP 2.
medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2021 Springer Healthcare Ltd, part of the Springer Nature Group